Kidney Injury Molecule-1 (KIM-1)

Kidney Injury Molecule-1 (KIM-1) is an immunoglobulin superfamily cell-surface protein that is highly upregulated on the surface of injured kidney epithelial cells. It is also known as TIM-1 (T cell immunoglobulin mucin domains–1), as it is expressed at low levels by subpopulations of activated T cells and hepatitis A virus cellular receptor–1 (HAVCR-1). KIM-1 expression is increased more than any other protein in the injured kidney and is localized predominantly to the apical membrane of the surviving proximal epithelial cells.

Swiss-Prot Accession Number: Q96D42


 
Therapy Indications
 
Myriad RBM Publications Publications
External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation (2019) Levitsky J, Asrani SK, Abecassis M, Ruiz R, Jennings LW, Klintmalm G Hepatology
Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes (2019) McCarthy CP, Shrestha S, Ibrahim N, van Kimmenade RRJ, Gaggin HK, Mukai R, Magaret C, Barnes G, Rhyne R, Garasic JM, Januzzi JL Open Heart
Biomarker panels associated with progression of renal disease in type 1 diabetes. (2019) Colombo M, Valo E, McGurnaghan SJ, Sandholm N, Blackbourn LAK, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM Diabetologia
Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation (2019) Levitsky J, Asrani SK, Klintmalm G, Schiano T, Moss A, Chavin K, Miller C, Guo K, Zhao L, Jennings LW, Brown M, Armstrong B, Abecassis M Hepatology
Biomarkers of diabetic kidney disease (2018) Colhoun HM, Marcovecchio ML Diabetologia
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II and III) Adult Subjexts (2018) Bunnell KL, Pai MP, Sikka M, Bleasdale S, Wenzler E, Danziger LH, Rodvold KA Antimicrobial Agents and Chemotherapy
A clinical and proteomics approach to predict the presense of obstructive peripheral arterial disease (From CASABLANCA) (2018) McCarthy CP, Ibrahim NE, van Kimmenade RRJ, Gaggin HK, Simon ML, Gandhi P, Kelly N, Motiwala SR, Mukai R, Magaret CA, Barnes G, Rhyne RF, Garasic JM, Januzzi JL Jr Clin Cardiol
Serum kidney injury molecule 1 and B2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes (2018) Colombo M, Looker HC, Farran B, Hess S, Groop L, Palmer CNA, Brosnan MJ, Dalton RN, Wong M, Turner C, Ahlqvist E, Dunger D, Agakov F, Durrington P, Livingstone S, Betteridge J, McKeigue PM, Colhoun HM Diabetologia
Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Undergoing Diagnostic Coronary Angiography (From the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study) (2017) McCarthy CP, Van Kimmenade R, Gaggin HK, Simon ML, Ibrahim NE, Gandhi P, Kelly N, Motiwala SR, Belcher AM, Harisiades J, Magaret CA, Rhyne RF, Januzzi Jr. JL Am J Cardiol
Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys. (2017) Chen Y, Dale Thurman J, Kinter LB, Bialecki R, Eric McDuffie J Toxicol Appl Pharmacol.
Evaluation of Novel Biomarkers of Nephrotoxicity in Cynomolgus Monkeys Treated with Gentamicin (2016) Gautier J-C, Zhou X, Yang Y, Gury T, Qu Z, Palazzi X, Léonard J-F, Slaoui M, Veeranagouda Y, Guizon I, Boitier E, Filali-Ansary A, van den Berg BHJ, Poetz O, Joos T, Zhang T, Wang J, Detilleux P, Li B Toxicology and Applied Pharmacology
High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia (2016) Wehler CA, Preskorn, SH Journal of Clinical Psychiatry
Altered Cerebrospinal Fluid Proteins in Smith–Lemli– (2016) Cologna SM, Shieh C, Toth CL, Cougnoux A, Burkert KR, Bianconi SE, Wassif CA, Porter FD American Journal of Medical Genetics Part A
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Biomarkers of rapid chronic kidney disease progression in type 2 diabetes (2015) Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, Wong MC, Turner C, Palmer CNA, Nogceke E, Groop L, Salomaa V, Dunger DB, Agakov F, McKeigue PM, Colhoun HM Kidney International
Characterization of Renal Biomarkers for Use in Clinical Trials: Effect of Preanalytical Processing and Qualification Using Samples from Subjects with Diabetes (2015) Brott DA, Furlong ST, Adler SH, Hainer JW, Arani RB, Pinches M, Rossing P, Chaturvedi N Drug Design, Development and Therapy
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent ß thalassaemia. (2014) Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL. Br J Haematol. 2014 Nov 17. doi: 10.1111/bjh.13217. [Epub ahead of print]
Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia (2010) Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, (JM) van Beveren N, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S Biomark Insights5: 39–47.
A guidance for renal biomarker lead optimization and use in translational pharmacodynamics (2010) Ozer JS Drug Discov Today15: 142-7.